Protalix BioTherapeutics (PLX) Raw Materials (2011 - 2026)
Protalix BioTherapeutics' quarterly Raw Materials came in at $6.0 million in Q1 2026, up 33.97% year-on-year from $4.5 million in Q1 2025, and little changed quarter-over-quarter from $6.0 million in Q4 2025.
Protalix BioTherapeutics has reported Raw Materials for 11 years, with the latest figure at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Raw Materials rose 33.97% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 33.97% YoY), and the FY2025 full-year result was $6.0 million, up 31.46% from the prior year.
- Raw Materials for Q1 2026 stood at $6.0 million, roughly flat from $6.0 million in the prior quarter.
- The five-year high for Raw Materials was $6.0 million in Q1 2026, with the low at $3.1 million in Q1 2022.
- Average Raw Materials over 5 years is $4.3 million, with a median of $4.3 million recorded in 2024.
- Year-over-year, Raw Materials decreased 10.53% in 2022 and surged 40.51% in 2023.
- Tracing PLX's Raw Materials over 5 years: stood at $3.5 million in 2022, then rose by 19.04% to $4.2 million in 2023, then climbed by 8.93% to $4.5 million in 2024, then surged by 31.46% to $6.0 million in 2025, then advanced by 0.45% to $6.0 million in 2026.
- The last three Raw Materials figures came in at $6.0 million (Q1 2026), $6.0 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 4.02 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 4.35 Mn |
| Mar 31, 2023 | 4.31 Mn |
| Dec 31, 2022 | 3.51 Mn |
| Sep 30, 2022 | 3.66 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.07 Mn |
| Dec 31, 2021 | 3.17 Mn |
| Sep 30, 2021 | 3.17 Mn |
| Jun 30, 2021 | 3.05 Mn |
| Mar 31, 2021 | 3.43 Mn |
| Dec 31, 2020 | 3.35 Mn |
| Sep 30, 2020 | 3.94 Mn |
| Jun 30, 2020 | 3.90 Mn |
| Mar 31, 2020 | 3.42 Mn |
| Dec 31, 2019 | 3.61 Mn |
| Sep 30, 2019 | 3.69 Mn |
| Jun 30, 2019 | 3.44 Mn |
| Dec 31, 2018 | 3.79 Mn |
| Jun 30, 2012 | 731,000.00 |
| Dec 31, 2011 | 279,000.00 |